[96a5a0]: / output / allTrials / identified / NCT06312176_identified.json

Download this file

495 lines (495 with data), 21.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
{
"info": {
"nct_id": "NCT06312176",
"official_title": "An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",
"inclusion_criteria": "* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer\n* Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor\n* Is a chemotherapy candidate\n* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization\n* Has adequate organ function\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Has breast cancer amenable to treatment with curative intent\n* Has experienced an early recurrence (<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment\n* Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications\n* Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease\n* Has an active infection requiring systemic therapy",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer",
"criterions": [
{
"exact_snippets": "unresectable locally advanced or metastatic",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"unresectable locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "centrally-confirmed hormone receptor positive (HR+)",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "human epidermal growth factor receptor 2 negative (HER2-)",
"criterion": "HER2 status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "breast cancer",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "breast"
}
]
}
]
},
{
"line": "* Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor",
"criterions": [
{
"exact_snippets": "radiographic disease progression",
"criterion": "radiographic disease progression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "one or more lines of endocrine therapy",
"criterion": "lines of endocrine therapy",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lines"
}
}
]
},
{
"exact_snippets": "unresectable locally advanced/metastatic HR+/HER2- breast cancer",
"criterion": "breast cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "unresectable locally advanced/metastatic HR+/HER2-"
}
]
},
{
"exact_snippets": "one in combination with a CDK4/6 inhibitor",
"criterion": "CDK4/6 inhibitor combination",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Is a chemotherapy candidate",
"criterions": [
{
"exact_snippets": "Is a chemotherapy candidate",
"criterion": "chemotherapy candidacy",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
}
]
},
{
"line": "* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization",
"criterions": [
{
"exact_snippets": "eastern cooperative oncology group (ECOG) performance status of 0 to 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "assessed within 7 days before randomization",
"criterion": "ECOG performance status assessment timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 7 days before randomization"
}
]
}
]
},
{
"line": "* Has adequate organ function",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy",
"criterions": [
{
"exact_snippets": "Human immunodeficiency virus (HIV)-infected participants",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "well controlled HIV on antiretroviral therapy",
"criterion": "HIV control",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "well controlled"
}
]
},
{
"exact_snippets": "antiretroviral therapy",
"criterion": "antiretroviral therapy",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load",
"criterions": [
{
"exact_snippets": "Hepatitis B surface antigen (HBsAg) positive",
"criterion": "Hepatitis B surface antigen (HBsAg)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "received HBV antiviral therapy for at least 4 weeks",
"criterion": "HBV antiviral therapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "undetectable HBV viral load",
"criterion": "HBV viral load",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": false
}
]
}
]
},
{
"line": "* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable",
"criterions": [
{
"exact_snippets": "history of Hepatitis C virus (HCV) infection",
"criterion": "Hepatitis C virus (HCV) infection",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "HCV viral load is undetectable",
"criterion": "HCV viral load",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": "undetectable"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Has breast cancer amenable to treatment with curative intent",
"criterions": [
{
"exact_snippets": "breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "amenable to treatment with curative intent",
"criterion": "treatment intent",
"requirements": [
{
"requirement_type": "intent",
"expected_value": "curative"
}
]
}
]
},
{
"line": "* Has experienced an early recurrence (<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment",
"criterions": [
{
"exact_snippets": "Has experienced an early recurrence (<6 months after completing adjuvant/neoadjuvant chemotherapy)",
"criterion": "early recurrence",
"requirements": [
{
"requirement_type": "time since chemotherapy",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "therefore is eligible to receive second-line (2L) treatment",
"criterion": "eligibility for second-line treatment",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
}
]
},
{
"line": "* Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications",
"criterions": [
{
"exact_snippets": "Has symptomatic advanced/metastatic visceral spread",
"criterion": "visceral spread",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
},
{
"requirement_type": "stage",
"expected_value": "advanced/metastatic"
}
]
},
{
"exact_snippets": "at risk of rapidly evolving into life-threatening complications",
"criterion": "risk of life-threatening complications",
"requirements": [
{
"requirement_type": "risk level",
"expected_value": "rapidly evolving"
}
]
}
]
},
{
"line": "* Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer",
"criterions": [
{
"exact_snippets": "Has received prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "unresectable locally advanced or metastatic breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"unresectable locally advanced",
"metastatic"
]
}
]
}
]
},
{
"line": "* Active autoimmune disease that has required systemic treatment in the past 2 years",
"criterions": [
{
"exact_snippets": "Active autoimmune disease",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "required systemic treatment in the past 2 years",
"criterion": "systemic treatment for autoimmune disease",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
]
}
]
},
{
"line": "* History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease",
"criterions": [
{
"exact_snippets": "History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids",
"criterion": "history of noninfectious pneumonitis/interstitial lung disease",
"requirements": [
{
"requirement_type": "treatment requirement",
"expected_value": "steroids"
}
]
},
{
"exact_snippets": "current pneumonitis/interstitial lung disease",
"criterion": "current pneumonitis/interstitial lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has an active infection requiring systemic therapy",
"criterions": [
{
"exact_snippets": "active infection requiring systemic therapy",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "systemic therapy"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}